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1. We investigated the role of Annexin (ANX)-A1 and its receptor, ALX/FPR2, in the regulation of mast cell de-
granulation produced by compound 48/80.
2. Both human cord-blood derivedmast cells (CBDMCs) andmurine bonemarrowderivedmast cells (BMDMCs)
release phosphorylated ANX-A1 during treatment with glucocorticoids or the mast cell ‘stabilising’ drugs
ketotifen and nedocromil.
3. Compound 48/80 also stimulated ANX-A1 phosphorylation and release and this was also potentiated by
nedocromil. Anti-ANX-A1 neutralising monoclonal antibodies (Mabs) enhanced the release of pro-
inﬂammatory mediators in response to compound 48/80.
4. Nedocromil and ketotifen potently inhibited the release of histamine, PGD2, tryptase and β-hexosaminidase
from mast cells challenged with compound 48/80. Anti-ANX-A1 neutralising Mabs prevented the inhibitory
effect of these drugs.
5. BMDMCs derived from Anx-A1−/−mice were insensitive to the inhibitory effects of nedocromil or ketotifen
but cells retained their sensitivity to the inhibitory action of hu-r-ANX-A1.
6. The fpr2/3 antagonistWRW4 blocked the action of nedocromil on PGD2, but not histamine, release. BMDMCs
derived from fpr2/3−/−mice were insensitive to the inhibitory effects of nedocromil on PGD2, but not hista-
mine release.
7. Compound 48/80 stimulated both p38 and JNK phosphorylation in CBDMCs and this was inhibited by
nedocromil. Inhibition of p38 phosphorylation was ANX-A1 dependent.
8. We conclude that ANX-A1 is an important regulator of mast cell reactivity to compound 48/80 exerting a neg-
ative feedback effect through a mechanism that depends at least partly on the FPR receptor.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Glucocorticoids (GCs) exert many acute anti-inﬂammatory effects
through the release of the 37 kDa protein Annexin-A1 (ANX-A1;
reviewed in [1,2]). In addition to increased transcription of Anx-A1
mRNA [3], exposure of target cells to GCs transiently activates PKC
through a non-genomic glucocorticoid receptor-dependentmechanism
[4] and phosphorylation of Serine-27 in the ANX-A1N-terminal domain
by activated PKC, promotes secretion of extracellular ANX-A1. FPR
receptors appear to be the main extracellular target for this protein
[5–7] with anti-inﬂammatory effects being triggered by ALX/FPR2
homo-dimerisation [8].
Mast cells are an abundant source of ANX-A1 and treatment with
anti-inﬂammatory glucocorticoids such as dexamethasone [9] or induc-
tion of inﬂammation [10–12] provokes rapid Anx-A1mRNA and/or new
protein synthesis.
The degranulation of mast cells can be prevented by glucocorticoids
utilising both a ‘fast’ and ‘slow’mechanisms [13] aswell as by the cromone
group of drugs [14].We have demonstrated that these latter drugs can act
synergistically with glucocorticoids in U937 cells by inhibiting the PP2A
phosphatase enzyme (EC 3.1.3.53) that normally limits the activation of
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PKC. This prolongs the time course of ANX-A1 phosphorylation, increasing
its release [15] and hence exerting an increased inhibitory action.
This mechanism underlies the ability of these drugs to inhibit neu-
trophil migration and mitigate intestinal reperfusion damage in the
mouse [14] as well as the inhibition of degranulation of human cord
blood-derived mast cells (CBDMCs) provoked by IgE cross-linking
[16]. Congruent with this notion, nedocromil is inactive in preventing
compound 48/80 or IgE/anti-IgE degranulation of bonemarrow derived
mast cells obtained from mice lacking the Anx-A1 gene [16].
To exclude the possibility that this was an effect only relevant to sig-
nalling through the high-afﬁnity IgE receptor, we here used compound
48/80 as a degranulating stimulus. This bypasses the high afﬁnity IgE re-
ceptor mechanism and acts directly on G-proteins to produce mast cell
degranulation.We are thus able to show that ANX-A1 is actually an en-
dogenous regulator of mast cell function, regardless of the mode of
stimulation, being phosphorylated and released during the degranula-
tion event itself and acting either wholly or partially, through the FPR
receptor system to regulate the limit and extent of mediator release.
The ANX-A1-FPR system can also be activated in the absence of degran-
ulation by drugs such as the glucocorticoids, the cromones and
ketotifen, which have the ability to prevent degranulation, and this
probably provides a clue to their mechanism of clinical action.
2. Materials and methods
2.1. Human cord-blood derived mast cells (CBDMCs)
CD34+ stem cells (Lonza, UK) used as a source andwere cultured as
previously described [16]. At week 8, un-stimulated CBDMCs were
immuno-phenotyped as N90% c-kit positive by FACS analysis. To further
conﬁrm the morphology, these cells were stained with toluidine blue
which stains the metachromatic granules of the mast cells. The cells
were maintained at a density of 1.0 × 106 cells/ml for no longer than
15 weeks.
2.2. Murine bone marrow derived mast cells (BMDMCs)
To generate primary bone marrow-derived murine mast cells
(BMDMCs), femur bones from Anx-A1−/− BALB/C, fpr2/3−/− C57/B6
and their respective WT control mice (4–6 weeks old, Charles River,
Kent, UK) were used. The method has been described in detail in a pre-
vious publication [16]. The differentiation of BMDMCs takes 4–6 weeks
and phenotypic maturity of these cells was checked before using the
cells for in-vitro experiments.
All animal workwas performed according to the UKHomeOfﬁce reg-
ulations (Guidance on theOperation of Animals, Scientiﬁc Procedures Act
1986) andwas approved by the QueenMary University of London Ethics
Committee (London, UK). Human cells were prepared according to a
protocol approved by the East London & The City Local Research Ethics
Committee (no. 06/Q605/40; P/00/029 ELCHA, London UK).
2.3. Treatment with drugs
CBDMCs/BMDMCs were stimulated with compound 48/80 (10 μg/
ml; Sigma-Aldrich, Dorset, UK) for 10 min at 37 °C with 5% CO2 atmo-
sphere. Drugs, antibodies or the FPR2/ALX antagonist (WRW4 peptide;
EMDChemicals, Darmstadt, Germany) tested in this systemwere added
5 min prior to the activation of compound 48/80. Samples were centri-
fuged at 1000 g for 5min before the cell-free supernatants were collect-
ed to measure histamine and PGD2 release. Cell lysates and supernatant
were prepared for Western blots. Sample aliquots were stored at
−80 °C for further analysis. Drugs such as the anti-allergic nedocromil
or the glucocorticoid dexamethasone were added as required. In some
cases the drug-treated cell aliquots were incubated with a well-
characterized speciﬁc neutralising anti-ANX-A1 (clone 1B; 20 μg/ml),
or an equivalent concentration of an isotype matched irrelevant (IgG1,
ABD Serotec, Oxford, UK), mAb.
2.4. Measurement of histamine release
A commercially available enzyme immunoassay was used to detect
and quantify histamine-released in the supernatant (SPI bio, Strasbourg,
France). The assay was conducted following the manufacturer's proto-
cols. A standard curve ranging from 0.39–50 nM histamine was pre-
pared using the reagent provided and the optical density was then
read within 60 min in a microplate reader (Titertek™, Vienna, Austria)
at 405 nm. In some cases, the total cell content of histamine was
established by freeze-thawing of cells prior to challenge.
‘Spontaneous histamine release’ was expressed as a percentage of
the amount (nmol) of histamine released in the absence of challenge di-
vided by the total histamine content of cells.
The ‘net histamine release’ was expressed as a percentage of the
amount (nmol) histamine released during challenge (corrected for the
spontaneous release) divided by the total histamine content of cells
(corrected for the spontaneous release).
2.5. Measurement of PGD2 release
A commercially available enzyme immunoassay (Cayman Chemical,
Michigan, USA) was used to detect and quantify PGD2 released in the
supernatant. The assay was conducted following the manufacturer's
protocols. A standard curve ranging from 78 to 10,000 pg/ml PGD2
was prepared using the reagent provided and the optical density was
then read within 60 min in a microplate reader (Titertek™, Vienna,
Austria) at 405 nm.
2.6. Assessment of Ser27 ANX-A1-P, PKC, p38, JNK and tryptase by Western
blotting
Ser27 ANX-A1-P and PKCwere assessed as previously described [16].
Total tryptase was assessed by using mouse monoclonal anti-tryptase
antibody (1:1000; Abcam, UK). Expression of phospho- and total JNK
and p38 MAPK (1:1000; Cell Signaling Technology, New England
Biolabs UK Ltd, Hitchin, UK) was assessed byWestern blot, as described
previously [15]. A horseradish peroxidase-conjugated secondary anti-
body (1:5000; Sigma-Aldrich, Poole, UK) detected bands related to the
proteins of interest and these were revealed using ECL reagents and
quantitated using the Image J densitometry program. All data were nor-
malised to total protein and expressed as percentage of control.
2.7. Subcellular distribution of PKC and ANX-A1 in cord blood derived mast
cells (CBDMCs)
CBDMCswere plated at a density of 2×105 cells in a 1.5ml Eppendorf
tube. Cells were treatedwith the stipulated drugs for 5min prior to stim-
ulation with compound 48/80. 2% PFA in 0.1 M PBS was added into the
Eppendorf tube for 10 min on ice to ﬁx the cells. Since the CBDMCs are
non-adherent cells, each immunostaining steps were performed in
1.5 ml Eppendorf tube and centrifuged at 1000 g for 5 min between
each methodological step and the supernatant was aspirated carefully
with a vacuum without disrupting the pellet. After ﬁxation, the cells
were washed with 0.1 M PBS. Cells were then permeabilised with 0.1%
Triton X-100 in PBS for 5 min. Non-speciﬁc secondary antibody binding
sitewere blocked by incubation of 10% FCS in PBS for 30min. Primary an-
tibodies (ANX-A1, α-rabbit, 1:1000, Invitrogen; α-mouse, 1:100, Abcam
and total PKCα-rabbit, 1:50, Cell Signaling Technology)was dilutedwith
1% FCS in PBS and left to incubate at 4 °C overnight. The cells were
washed twice with 1% FCS in PBS and incubated with ﬂuorescent-
labelled secondary antibody (Alexa Fluor 488, green and Alexa Fluor
546, red) for 1 h at room temperature. The cells were then washed
with PBS and stained with 100 ng/ml DAPI (Invitrogen) in ddH2O for
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5 min. The cells were washed with 30 μl ddH2O and dropped onto the
slide using a pipette. Cover slips were carefully mounted onto the slides
using the ProlongGoldMountant (Invitrogen). Slideswere then analysed
and micrographs were taken using the confocal microscope (Leica) at
63× magniﬁcation.
2.8. Statistical analyses
Where the data satisﬁed the conditions (e.g. Gaussian distribution),
we used ANOVAwith the Bonferroni post-hoc correction. In some cases
where only two columns of datawere analysed,we used Student's T test
(unpaired).
2.9. Drugs and reagents
Nedocromil sodium was generously supplied by Sanoﬁ-Aventis
(Paris, France), dexamethasone was obtained from Sigma-Aldrich
(Poole, Dorset, UK). The drugs were made freshly on the day of every
experiment.
3. Results
3.1. Prolongation of GC-induced PKC phosphorylation by nedocromil
We have previously observed that PKC activation is responsible for
the phosphorylation of ANX-A1 in theU937 cells [15] and the samephe-
nomenon is observed in CBDMCs [16].
GCs such as dexamethasone activate PKC by a non-genomic receptor
basedmechanismprobably involving PI3 kinase [4,17] and in U937 cells
we have determined that nedocromil synergises with effects of dexa-
methasone by prolonging PKC phosphorylation secondary to inhibition
of the PP2A phosphatase [15].
We conﬁrmed our previous observation that nedocromil action is
dependent upon PKC by testing the effect of an inhibitor of PKC on the
effect of nedocromil on the appearance of ANX-A1 Ser-27 in CBDMCs.
Using a densitometry analysis (n = 3; Suppl. Fig. 1) we found that the
PKC inhibitor Gö 6983 (10 μM) not only reduced the basal level of
ANX-A1 Ser-27 from 104.6 ± 2.4 AD units to 29.88 AD units but also
completely reversed the potentiation of phosphorylation (1.3-fold)
seen after treatment with 10 nM nedocromil reducing it from
135.3 ± 1.1 AD units to 48.6 ± 8.5 AD units.
We chose 5 min time point to treat CBDMCs with nedocromil as we
have shown previously that the optimal effect of nedocromil was seen
by 5 min at which time the amounts of ANX-A1 Ser-27 had increased by
2.1 ± 0.20 fold and the amounts of phospho-PKC by 3.6 ± 0.23 fold [16].
We did notmeasure inhibition of PP2Aby nedocromil directly in this
study (although we did so in a previous publication [15]) but instead
used a surrogate measure to check that this drug acts in a manner con-
sistent with our previous reports. PP2A terminates the activity of PKC
thus reducing its dwell time at the plasma membrane when activated.
To ascertain whether this was seen in CBDMCs, we pre-treated these
cells with either 10 nM of nedocromil, 2 nM of dexamethasone or
both drugs in combination for various time points (0–60 min).
Fig. 1 (panel A), shows that, as expected, treatmentwith nedocromil
alone provoked very weak PKC phosphorylation that was maximal by
5–10 min. Treatment with dexamethasone alone produced a burst of
PKC phosphorylation which resulted in some co-localisation of ANX-A1
and PKC at the cell membrane although this was ﬁnished by 5min. How-
ever, when both drugs were used in combination the time course of PKC
phosphorylation was prolonged reaching a maximum at 20–40 min.
When activated, PKC translocates to the plasmamembrane where it
is co-located with its substrates (in this case ANX-A1) and where it
is subsequently inactivated by PP2A prior to recycling and/or
ubiquitination by the cell [18]. Any prolongation of PKC activity due to
inhibition of PP2A would therefore be reﬂected by an increased dwell
time of the enzyme in association with ANX-A1 at the cell membrane.
Fig. 1 panel B shows an experiment where analysed the effects of
these drugs on PKC dwell time in CBDMCs using confocal microscopy.
The CBDMCs were stained for total PKC (red; Alexa Fluor 546; anti-
rabbit) and total ANX-A1 (green; Alexa Fluor 488; anti-mouse).
CBDMCs were treated with dexamethasone (2 nM) alone or in combi-
nation with nedocromil (10 nM) across various time points. In this ex-
periment, nedocromil produced barely detectable activation of PKC
alone compared with untreated cells (not shown) and similar cytoplas-
mic distribution of total PKC and ANX-A1 was seen at 5, 10 and 20 min
(left hand composite). PKC was observed mainly in the cytoplasmic or
peri-nuclear region apparently associated with vesicles. Some ANX-A1
was clearly localised at the plasma membrane but there was no co-
localisationwith PKC. However, when CBDMCswere treatedwith dexa-
methasone for 5min (central composite), some co-localisation atmem-
brane level between total PKC and ANX-A1 at 5 min but this effect was
notmaintained. Following exposure to both nedocromil and dexameth-
asone (right hand composite) substantial amounts of PKC translocated
to the plasma membrane and co-localised with ANX-A1 and this effect
was still observed at 20 min.
3.2. Compound 48/80 promotes Anx-A1 phosphorylation and release in a
concentration dependent manner in CBDMCs
Wenext tested the ability of compound 48/80 alone to release hista-
mine from CBDMCs. Since preliminary experiments suggested that
20 μg/ml compound48/80 already promotedmaximalmast cell degran-
ulation (60–80%) and we wanted to avoid possible pitfalls associated
with maximal stimulation of cells, we investigated the effect of lower
concentrations of compound 48/80 ranging from 0.01–10 μg/ml.
Fig. 2 panel A, shows that compound 48/80 produces a linear in-
crease in histamine release from concentrations ranging from 0.01 to
0.1 μg/ml, but that thereafter the effect reaches a plateau at ~60% of
net histamine release in concentrations from 1 to 10 μg/ml. As concen-
trations of compound 48/80 in the range of 0.01–0.1 μg/ml promote
only about 10–30% of net histamine release, we used these concentra-
tions to investigate the ability of compound 48/80 to induce Anx-A1
phosphorylation.
Fig. 2 panel B, shows the disposition of intra- and extracellular
phospho ANX-A1 in response to graded concentrations of compound
48/80 as assessed by Western blotting. Compound 48/80 induces a
concentration-dependent increase in ANX-A1 phosphorylation at the
Ser-27 residue, and promotes its release into the medium even in con-
centrations when it produces only small effects (b20%) on histamine
release.
The time course of the response to compound 48/80 (0.05 μg/ml)
was tested in conjunction with nedocromil in Fig. 2 panels C and D.
Here, Western blotting quantitated by densitometry assessed the total
Ser-27 phospho ANX-A1. The effect of compound 48/80 (1.4 fold in-
crease) was observed to be transient with a maximum at 5 min. The ef-
fect of 10 nM nedocromil (2.7 fold increase) was also maximal at 5 min
although it was still detectable at 40 min. However, a combination of
both agents produced an intense (4.5 fold increase) and a long lasting
(N40 min) stimulation of ANX-A1 phosphorylation.
From these experiments we conclude that 48/80, in addition to acti-
vating CBDMC degranulation, also stimulates ANX-A1 phosphorylation
and that this is itself prolonged by the action of nedocromil.
3.3. The inhibition by nedocromil (10 nM) of compound 48/80 induced his-
tamine, PGD2, β-hexosaminidase and tryptase release by CBDMCs is re-
versed by anti-ANX-A1 neutralising antibodies
To determine the role of ANX-A1 in promoting the stability of mast
cells, the effect of a speciﬁc neutralising monoclonal anti-ANX-A1 mAb
was tested. We have previously reported [16] that the inhibitory effect
of nedocromil on IgE/anti-IgE cross-linking induced degranulation of
CBDMCs is reversed in the presence of anti-ANX-A1 mAbs. To test
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whether this was a general effect of degranulating agents, we here used
as the stimulus compound 48/80, which bypasses the high-afﬁnity IgE
receptor dependent mechanism of cell activation.
CBDMCs were pre-incubated for 20 min with 20 μg/ml neutralising
anti-ANX-A1 mAb 1B, or an equivalent concentration of an irrelevant
isotype-matched mAb prior to treatment with nedocromil and com-
pound 48/80. We also tested ketotifen as we have previously reported
that this drug, which is chemically distinct from the cromones, exerts
similar effects to nedocromil.
We observed (Fig. 3) that 10 min stimulation of CBDMCs with
10 μg/ml of compound 48/80 provoked the release of approximately
44% of net histamine release, and 1520 pg/ml of PGD2. We also mea-
sured the net β-hexosaminidase (Suppl. Fig. 2) and tryptase content
of the cells (Suppl. Fig. 3) following treatment. β-Hexosaminidase
release was strongly stimulated (57.4 ± 1.6% pNA units) whilst the
cell content of tryptase was reduced to 65.5 ± 8.2% of control by
compound 48/80 (p b 0.01).
Pre-treatment with nedocromil prior to compound 48/80 stimula-
tion signiﬁcantly (p b 0.001) inhibited the release of histamine by
73.5% and PGD2 by 59% (p b 0.01). Nedocromil also inhibited β-
hexosaminidase release by 44% (to 32.08 ± 0.78 pNA units; p b 0.01)
and reduced the release of tryptase from 65.5% to 10.1% (90.8 ± 0.90
units). However, in the presence of the neutralising anti-ANX-A1mono-
clonal antibody, these inhibitory actions of nedocromilwere completely
abolished.
Interestingly, examination of the data suggested that the neutralising
(but not the isotype-matched control) monoclonal anti-ANX-A1 mAb
alone exhibited a tendency to enhance the release of mediators in the
presence of compound 48/80. For example, in Fig. 3, the release of hista-
mine stimulated by compound 48/80 was increased from 45.6 ± 2.26 to
54.52± 1.18% (p b 0.01) and the release of PGD2 from 1432.77± 175.77
to 1515.91 ± 127.84 pg/ml (p b 0.01).
The amount of intracellular tryptase remaining after compound 48/
80 was decreased from 65.5 ± 6.83% to 53.6 ± 6.73 (although this did
not achieve statistical signiﬁcance) in the presence of the neutralising
anti-ANX-A1 monoclonal (but not the isotype-matched control).
The release of β-hexosaminidase was also increased in the presence
of the neutralising anti-ANX-A1 monoclonal from 57.37 ± 1.60 to
67.96 ± 4.44 pNA units (p b 0.01). In this connection, we also observed
(Suppl. Fig. 2; panel B) that even the addition of the neutralising anti-
ANX-A1mAb to resting, unstimulated CBDMCs increased the spontane-
ous release of β-hexosaminidase from 8.9 ± 0.3% to 43.6 ± 3.6%
(p b 0.001). All these data suggest that without some external ANX-
A1, CBDMCs can undergo partial spontaneous degranulation even in
the absence of an added stimulus.
3.4. Effect of nedocromil and ketotifen on compound 48/80 induced
mediator release in BMDMCs from Anx-A1 null mice
To further conﬁrm the role of Anx-A1 in the inhibition by
nedocromil and ketotifen we tested the activity of these drugs on
BMDMCs derived from Anx-A1 null mice. Fig. 4 shows that both
nedocromil and ketotifen are able to produce inhibition of both hista-
mine (43.6% and 30% respectively) and PGD2 (61.04% and 58.1%
Fig. 1.Nedocromil prolongs the dexamethasone stimulation of PKC phosphorylation and increases the dwell time of PKC at the CBDMC plasmamembrane. Panel A:Western blot analysis
of PKC phosphorylation at different time points in CBDMCs treatedwith nedocromil (10 nM; LH block), dexamethasone (2 nM; centre) or both in combination (RH block). Increased PKC
phosphorylation is detectable at 5 min and peaks at 10minwhen CBDMCs were treated with nedocromil and at 5 min following treatment with dexamethasone. In the presence of both
dexamethasone and nedocromil, phosphorylation of PKC is potentiated by 4 fold at 40min. Blots are a representative of 3 independent experiments. Panel B: The confocal images show a
complementary experiment to that in panel A. The three columns represent the information from the two colour channels and the merged channel. Cells were stained for total PKC (red;
Alexa Fluor 546; anti-rabbit) and total ANX-A1 1B (green; Alexa Fluor 488; anti-mouse). Themicrographs of untreated CBDMCs (left hand block) show similar cytoplasmic distribution of
total PKC andANX-A1 across various time points. There is some localization of ANX-A1, but not PKC, at themembrane. The effect of nedocromil alone on the co-localisation of ANX-A1 and
PKC was undetectable and indistinguishable from untreated cells. Cells treated with dexamethasone (middle block) for 5 min shows that there is some co-localisation of PKC and ANX-
A1 at membrane (white arrow). However, this had disappeared by 10 min. Cells treated with both dexamethasone and nedocromil for 5 min (right hand block) shows that there is a
striking degree of co-localisation at the membrane level between total PKC and total ANX-A1 (white arrows) and this persisted for 20 min, suggesting that nedocromil prolonged the
activity of PKC at the membrane level probably by inhibiting the PP2A enzyme. The images were taken at 63× oil magniﬁcation. Scale bars: 10 μm. This composite ﬁgure is
representative of three independent experiments.
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respectively) release in wild type BMDMCs but not in cells derived
from Anx-A1 null mice. However, inhibition of mediator release
could still be achieved by reconstituting the system with hu-r-Anx-
A1 itself, which inhibited histamine and PGD2 release by 66.5% and
69.34% respectively.
3.5. The role of the FPR receptor system in the inhibitory action of
nedocromil
In many systems, the response of the cell to ANX-A1 is dependent
upon the presence of the FPR receptor system (e.g. [2,5]) and these
Fig. 2. Compound 48/80 itself stimulates histamine release, PKC and Anx-A1 phosphorylation in CBDMCs in a concentration-dependent manner and this is potentiated by nedocromil.
Panel A. Exposure of CBDMCs to compound 48/80 (0.01–0.1 μg/ml) caused a concentration-dependent release of histamine reaching a maximum (~55% total cellular histamine) at a
concentration of 10 μg/ml. Data are expressed as mean ± SEM of n = 3 experiment (***p b 0.001). Panel B. Exposure of CBDMCs to compound 48/80 (0.01–0.1 μg/ml) is accompanied
by a concentration-dependent increase in Ser-27 phospho ANX-A1 and release of the protein from the cell into the surrounding medium (representative example from 3 blots). Panel
C. When assessed by Western blotting techniques, the phosphorylation of ANX-A1 induced by nedocromil (10 nM) or compound 48/80 (0.05 μg/ml) alone decreases after 10 min,
however when the two are combined, the effect of compound 48/80 persists for 30 min (representative example from 3 blots). Panel D. A graphical representation of the densitometry
analysis of panel C illustrating this effect. The values are expressed as mean ± SEM (n = 3). *p b 0.05 and **p b 0.01 vs untreated samples; ♯♯p b 0.01 and ♯♯♯p b 0.001 vs compound
48/80 values; §§§p b 0.001 vs compound 48/80 + nedocromil values).
Fig. 3. The inhibition by nedocromil and ketotifen of mediator release from CBDMCs stimulated with compound 48/80 is dependent upon Anx-A1. CBDMCs were plated at a density of
2 × 105 cells per well and the stipulated groups were treated with 20 μg/ml ANX-A1 neutralising antibody or an irrelevant isotype control. Subsequently, the cells were pre-treated
with nedocromil (10 nM) for 5 min followed by compound 48/80 (10 μg/ml) stimulation for 10 min. To assess the effects of ANX-A1 removal, the cells were incubated with the ANX-
A1 neutralising antibody (or an irrelevant isotype control) only. The supernatants were collected from the samples and assessed for histamine (top panel) and PGD2 (lower panel).
Nedocromil produced consistent inhibition of histamine and PGD2 release, but this was abrogated in the presence of the immuno-neutralising mAb, but not the control reagent. Data
are expressed as mean ± SEM from n = 3 experiment and were analysed using one-way analysis of variance (ANOVA), followed by a Bonferroni post-hoc test, *p b 0.05, **p b 0.01,
***p b 0.001 vs unstimulated).
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Fig. 4. The inhibitory action of nedocromil and ketotifen is dependent upon the presence of mast cell Anx-A1. BMDMCs from both Anx-A1+/+ (panels A and B) and Anx-A1−/− (panels C
and D)mice were cultured and prepared as described. The cells were incubatedwith either nedocromil (10 nM) or ketotifen (10 nM) and, in the case of the Anx-A1−/− cells, 10 nMhu-r-
Anx-A1. From panels A and B it can be seen that both nedocromil and ketotifen inhibit histamine (43.6 and 30% respectively) aswell as PGD2 (61.04% and 58.1% respectively). These drugs
do not produce signiﬁcant inhibitory actions in the Anx-A1−/− cells (panels C and D) although hu-r-Anx-A1 retains its potent activity demonstrating that this is not caused by a failure of
the cells to respond. *0.05 b p; **0.01; ***0.001 vs stimulated release; n = 5.
Fig. 5. The role of FPR receptors in the inhibitory action of nedocromil in CBDMCs and BMDMCs. Nedocromil (10 nM; panel A) inhibited the release of histamine from CBDMCs stimulated
with compound 48/80 (10 μg/ml). The FPR2 antagonistWRW4 (10 μM) alone partially inhibited the release of histamine but had little effect on the inhibitory action of nedocromil. In the
case of PGD2 however (panel B),WRW4 substantially reversed the inhibitory effect of nedocromilwhile having no signiﬁcant effect itself on the release of PGD2 (*0.05 b p; **0.01; ***0.001
vs stimulated release; n = 6). In the case of BMDMCs, nedocromil was found to exert a concentration-dependent inhibition of histamine release in bothWT and fpr2/3 null mice (panel
C) whereas nedocromil was without effect on the release of PGD2 from cells derived from the fpr2/3 null mice whilst producing the expected inhibition in WT cells (panel D). Data are
expressed as mean ± SEM from n = 3 experiment and were analysed using one-way analysis of variance (ANOVA), followed by a Bonferroni post-hoc test, *p b 0.05, **/++ p b 0.01,
***p b 0.001 vs control.
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receptors are present on mast cells (see e.g. [19,20]). Here, we tested
whether this is also true for the inhibition produced by nedocromil on
histamine and PGD2 release.
Fig. 5, panels A and B show a set of experiments using CBDMCs in
which the FPR2 antagonist WRW4 (10 μM) was used as a probe for
receptor involvement. Nedocromil alone (10 nM) produced ~60–70% in-
hibition of histamine and PGD2 release stimulated by compound 48/80,
but while the effect on PGD2 release was greatly reduced in the cells
treated with WRW4, the inhibition of histamine release by nedocromil
was not altered.
Panels C and D show experiments in which BMDMCswere prepared
from fpr2/3 (themurine analogue of FPR2) nullmice orWT controls and
stimulatedwith compound 48/80. Here, a similar patternwas observed.
Whilst the effect of nedocromil on histamine release was still present in
the fpr2/3 null cells, it no longer produced a concentration dependent
inhibition of PGD2 release.
3.6. Role of downstream signalling in nedocromil action on CBDMCs
Both JNK and p38 have been identiﬁed as important components of
signalling cascades in leading to mediator release in human blood baso-
phils [21] aswell as human [22] and rat [23] intestinalmast cells, and rat
basophilic leukaemia mast cells [24].
We have previously reported that activation of FPR2 homo-
dimerisation in transfected HEK293 cells activated p38 MAPK pathway
whereas activation of FPR1/FPR2 heterodimers activated a JNK mediat-
ed signalling pathway [8].
To testwhether these signalling factors were important in the inhib-
itory effect of nedocromil on mast cells and whether this was Anx-A1
dependent we measured the phosphorylation of p38 and JNK in
CBDMCs following compound 48/80 treatment using Western blotting
techniques.
Fig. 6 shows the results. Treatment of CBDMCs with compound 48/
80 activated JNK as measured by the appearance of increased amounts
of p-JNK following exposure. This was blocked if the cells were pre-
treated with nedocromil and this did not appear to be ANX-A1 depen-
dent as there was no change following incubation of the cells with the
neutralising anti-ANX-A1 monoclonal. In contrast, whilst nedocromil
also inhibited the activation of p38 following compound 48/80, this in-
hibitory activity was reversed in the presence of the anti-ANX-A1
monoclonal suggesting that activation of this signalling pathway was
ANX-A1 dependent.
4. Discussion
Our previous publications in this area highlighted a novel mecha-
nism of action for the cromone anti-allergic drugs. Using a U937 cell
model we demonstrated [15] that the export of Anx-A1 stimulated by
the glucocorticoid dexamethasone was greatly potentiated by
nedocromil or cromoglycate and that this increased the biological activ-
ity of the glucocorticoid as an inhibitor of eicosanoid production by
these cells. We observed that the reason for the effect was that in the
presence of cromones, the stimulatory action of the liganded GR was
greatly prolonged and that this appeared to be due to an inhibitory ef-
fect of these drugs on PP2A, the enzyme that normally de-activates
PKC thus terminating its activity.
In a subsequent study, we demonstrated that the ability of
cromones to inhibit CBDMC degranulation stimulated by IgE–anti-
IgE cross-linking was prevented by immuno-neutralisation of Anx-
A1 and was wholly absent in the BMDMCs from Anx-A1 null mice
[16].
Whilst the cromones are known mainly as anti-allergic drugs, they
havemany other pharmacological actions including inhibition of leuko-
cyte migration. We further showed [14] that the ability of cromones to
produce this anti-migratory effect was not only dependent upon Anx-
A1 externalisation, but also on the presence of FPR receptors on the leu-
kocyte surface. In this study we have conﬁrmed and extended these
ﬁndings.
It has been known for many years that both PKC and PP2A are
translocated to the membrane during mast cell activation whether
this is caused by antigen cross-linking at the high afﬁnity IgE receptor
or agents that bypass this receptor [25,26]. It is the phosphorylation of
target proteins (such as myosin) on the cell membrane by PKC that ini-
tiates the process of secretion. PP2A, which regulates PKC activity in this
respect, has been identiﬁed as a key enzyme in the regulation of mast
cell reactivity and treatment of mast cells with okadaic acid inhibits se-
cretion of mediators [26].
In this study PP2A translocation and activity was assessed indirectly
inmast cells bymonitoring the length of time that PKC is resident at the
membrane following cell activation. Our idea that nedocromil prolongs
PKC activation by decreasing the activity of PP2A enzyme was further
supported by our observation here that this drug prolongs the translo-
cation of PKC to the cell membrane. This is also consistentwith previous
reports in the literature that treatment of mast cells with cromones in-
creases the phosphorylation of proteins thought to be involved in the
exocytotic mechanism [27,28].
Fig. 6. Downstream signalling in CBDMCs is differentially altered by nedocromil. Compound 48/80 (10 μg/ml) stimulation of CBDMCs increased p-38 and JNK phosphorylation, and this
was inhibited by nedocromil (10 nM). The presence of ANX-A1 neutralising antibody reversed the phospho-p38 inhibitory actions of nedocromil but did not alter its inhibitory actions on
JNK phosphorylation. Data are expressed as mean ± SEM (n = 3 independent experiments; ***p b 0.001 vs unstimulated).
93A. Sinniah et al. / International Immunopharmacology 32 (2016) 87–95
Here we have observed that in addition to glucocorticoid/cromone
treatment, compound 48/80 itself activates PKC, promotes the phos-
phorylation and release of ANX-A1 and that this too, is potentiated by
nedocromil.
This ﬁnding points to a way by which the intensity of the
degranulating stimulus is matched by an increased release of inhibitory
ANX-A1 so as to regulate the overall magnitude of the secretory re-
sponse. It also raises an interesting question: could nedocromil (or
other cromone) actually potentiate mast cell degranulation provoked
by agents such as compound 48/80 in the absence of ANX-A1?
Some support for this idea arises from our ﬁndings using immuno-
neutralisation of ANX-A1. This biologic not only abrogates the inhibitory
effect of both nedocromil and ketotifen but also, interestingly, we ob-
served that there was a strong trend for the neutralising mAb alone to
promote mediator secretion when the mast cells were stimulated.
This certainly would ﬁt with the general conclusion that this is an en-
dogenous regulatory molecule.
Whilst we have previously published on the importance of ANX-A1
in the inhibitory action of cromones inmast cells stimulated by IgE–anti
IgE or DNP-BSA/anti-DNP-IgE cross-linking [16], we could not rule out
that this was an effect speciﬁc to signalling through the high afﬁnity
IgE receptor. In this study, we can now conﬁrm that similar results are
seenwhen the stimulating agent is compound 48/80, which acts direct-
ly on G proteins to stimulate the secretory event [29]. We also report
here other novel ﬁndings, including the observation that inhibition of
the release of other mast cell mediators such as β-hexosaminidase and
tryptase by nedocromil is similarly ANX-A1 sensitive.
Of interest therefore is the notion that under conditionswhere ANX-
A1 becomes ‘depleted’ – for example, after repetitive challenge with
degranulating agents, glucocorticoids or cromones – then the inhibitory
response of the latter agents will be temporarily lost. We have indeed
observed this in the case of prolonged hydrocortisone stimulation of
macrophages [30].
The results of the experiments in which we tested the ability of
nedocromil and ketotifen to inhibit histamine and PGD2 release in
BMDMCs is entirely congruent with the neutralisingmonoclonal exper-
iments and the fact that the ANX-A1 null cells still respond to Anx-A1
establishes that the receptor system is still present on these cells. In
fact, the role of the FPR receptor family in the response of mast cells to
nedocromil is of particular interest. In many systems, ALX/FPR2 is the
chief subtype throughwhichANX-A1, and other anti-inﬂammatory reg-
ulators such as Resolvin D1 and Lipoxin A4, exert their inhibitory actions
[2,5,6].
Since either deletion of Anx-A1 altogether (as in the KO mouse) or
its removal using neutralising monoclonals clearly establish that this
protein is a vital component of nedocromil action, onewould anticipate
that removal of the principal receptor for Anx-A1, FPR2 (or its murine
homologue) fpr2/3 would prevent the action of this drug as well.
Our observations here suggest that this is only partially true. Whilst
the blockade of the FPR2 receptor in CBDMCs or its removal in the fpr2/
3-null BMDMCs clearly prevented the action of nedocromil on PGD2
generation and release, it failed to completely block inhibitory action
on histamine release.
This apparent paradox might be understood in terms of the possible
involvement of other members of the FPR family. In a previous study,
we observed that the inhibitory effect of nedocromil on the migration
of PMN in a cell chamber model of migration was dependent upon the
presence of both FPR1 and FPR2 receptors [14]. Cooray et al. [8] showed
that whilst full-length ANX-A1 produced FPR2 homo-dimerisation and
activated the p38 signalling pathway in HEK293 cells, N-Ac-2-26, an
N-terminal peptide of ANX-A1, produced hetero-dimerisation of FPR1/
2, and activated a different, JNK-dependent, signalling pathway.
It is therefore possible that the effect of ANX-A1 on mast cells is the
result of a combination of signalling produced by the full-length protein
as well as a clipped fragment such as N-Ac-2-26, which acts as a ligand
at both FPR1 and FPR2/ALX [8]. In fact several groups have highlighted
the role of proteases in the cleavage of ANX-A1 in mast cells in lung ex-
tracts from ovalbumin sensitised mice, RBL-2H3 cells [31] as well as en-
dometrial tissue [32] so this is a distinct possibility.
The signalling data that we present also poses further questions.
Many authors have commented on the roles of MAPK pathways in
mast cell activation (e.g. [13]. The p38 MAPK pathway has been impli-
cated in the generation of PGD2 in RBL-2H3 cells [24], sequential activa-
tion of p38 and JNK pathways is responsible for substance P induced
TNF and histamine release from rat peritoneal mast cells [23]. Others
have pointed out that there are apparently differences in the utilisation
of MAPK members in different cells bearing the IgE receptor [21].
Given that any signalling through an ANX-A1 pathway in our system
is likely through FPR receptors, our data would suggest that the effect of
nedocromil on p38 activation is a direct result of signalling through the
FPR receptor system, aswe have observed previously [8] but that the ac-
tivation of JNK is a further action of nedocromil unrelated to this signal-
ling pathway. It is possible that this is an indirect action of nedocromil,
which perhaps produces this effect by inhibition of a phosphatase at
some other point in the signalling cascade.
In summary, we have highlighted evidence supporting the case that
ANX-A1 is an important endogenous regulator of mast cell function,
which tonically inhibits activation in a ‘resting’ state and which is se-
creted in increased amounts in parallel with mediators when these
cells are activated and acts to limit the extent of the degranulation and
activation response.
The ‘fast’ glucocorticoid response [13] in mast cells is probably
brought about by the release of ANX-A1 and in the cromone anti-
allergics, investigators empirically discovered a group of compounds
that could exploit this mechanism by releasing ANX-A1 in the absence
of degranulation, thereby inhibiting subsequent responses.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.intimp.2016.01.003.
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